CLOs on the Move

Patheous Health

www.patheous.health

 
Patheous Health is a company that specializes in dysphagia healthcare and swallowing impairment conditions. They offer an Integrated Dysphagia Healthcare (iDH) platform and provide service solutions for both MBS and FEES studies.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Transit Resources Inc

Transit Resources Inc is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biodex

Biodex Medical Systems, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Biodex Medical Systems, Inc. is based in Shirley, NY. You can find more information on Biodex Medical Systems, Inc. at www.biodex.com

vante

vante is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeCare Hospitals

LifeCare Hospitals is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. LifeCare Hospitals is based in Plano, TX. You can find more information on LifeCare Hospitals at www.lifecare-hospitals.com

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.